PEPTIDE RESEARCH TOPIC

Retatrutide (Reta) Research Peptide

Explore Retatrutide research information, terminology, development identifiers, comparisons, and frequently searched questions.

TOPIC OVERVIEW

About Retatrutide

Identity and names

Retatrutide is the accepted name for the investigational compound also identified as LY3437943 or LY-3437943.

  • Reta is informal shorthand rather than a separate peptide.
  • Development codes identify the compound studied in sponsored trials and should not be treated as proof that an online material is equivalent.

Compound type

Retatrutide is an acylated peptide designed as a single GIP, GLP-1, and glucagon receptor agonist.

  • Its lipid side chain promotes albumin binding and extends exposure compared with native gut hormones.

Mechanism

The molecule activates three related metabolic-receptor pathways.

  • GIP and GLP-1 receptor activity is studied in glucose-dependent insulin signaling, while glucagon receptor activity adds research questions involving energy expenditure and hepatic metabolism.

Research focus and evidence

Research includes receptor pharmacology, metabolic endpoints, body-weight regulation, glucose control, and organ-specific outcomes.

  • Human development has reached Phase 3 studies, but results remain tied to each trial's formulation, population, endpoints, and quality controls.

Regulatory status and limits

Retatrutide remains an investigational compound rather than a generally approved medicine in the United States.

  • Research-labeled material cannot be assumed to match clinical-trial material in identity, purity, sterility, concentration, or biological performance.
Topics covered
  • mechanism and receptor terminology
  • research-stage evidence
  • storage and handling
  • purity and COA interpretation
  • comparisons with related peptides
Common names and related terms: retatrutide, reta, ly3437943, ly-3437943
RESEARCH TRACKER

Retatrutide Development & Clinical Research

Current programs, research areas, study status, enrollment, and expected completion dates organized from primary registry records.

LAST VERIFIEDSeptember 30, 2026
Registered records33
Active studies11
Completed studies21
Phase 3 studies14
DeveloperEli Lilly and Company
AliasesLY3437943, LY-3437943, Reta
Biological targetsGIP receptor, GLP-1 receptor, Glucagon receptor
Development stagePhase 3
Regulatory statusInvestigational; not FDA-approved

What current projects are studying

Obesity and overweightType 2 diabetesCardiovascular and kidney outcomesWeight maintenanceMASLD and liver outcomesChronic low back painInsulin secretion and sensitivity
SELECTED CURRENT RESEARCH

Latest and important projects

Showing 5 of 11 active studies
REGISTERED STUDYNCT07165028

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease

Phase
Phase 3
Status
Recruiting
Enrollment
4,500 Estimated
Expected completion
Aug 2032
Record updated
Sep 22, 2026
Lead sponsor
Eli Lilly and Company
REGISTERED STUDYNCT06297603

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Type 2 Diabetes

Phase
Phase 3
Status
Active, not recruiting
Enrollment
320 Estimated
Expected completion
Nov 2026
Record updated
Jul 20, 2026
Lead sponsor
Eli Lilly and Company
TRIUMPH-5NCT06662383

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Obesity

Phase
Phase 3
Status
Active, not recruiting
Enrollment
800 Estimated
Expected completion
Dec 2026
Record updated
Jul 20, 2026
Lead sponsor
Eli Lilly and Company
REGISTERED STUDYNCT06260722

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Diabetes Mellitus, Type 2

Phase
Phase 3
Status
Active, not recruiting
Enrollment
1,250 Estimated
Expected completion
Feb 2027
Record updated
Sep 28, 2026
Lead sponsor
Eli Lilly and Company
TRIUMPH-8NCT07232719

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Obesity · Overweight

Phase
Phase 3
Status
Active, not recruiting
Enrollment
250 Estimated
Expected completion
Jul 2027
Record updated
Apr 17, 2026
Lead sponsor
Eli Lilly and Company
Primary sources: ClinicalTrials.govRecords are included when the intervention name or an intervention alias matches Retatrutide or LY3437943. Active studies include recruiting and active, not recruiting records.

Registry status does not establish safety, efficacy, or regulatory approval.

START HERE

Essential Retatrutide guides

RETATRUTIDE KNOWLEDGE ARTICLESPage 1 of 27
04
KNOWLEDGE ARTICLE

Can You Mix MOTS-c and Retatrutide Together?

Can you mix MOTS-c and retatrutide together? No human studies exist on this combination. Here's what each compound does and the risks to weigh first.

↗
07
KNOWLEDGE ARTICLE

Novo Pro Labs Retatrutide Reviews: What to Know

Novo Pro Labs retatrutide reviews are hard to verify. Here's how to judge vendor claims, check third-party testing, and stay safe in the US market.

↗
13
KNOWLEDGE ARTICLE

Onyx Research Peptides Retatrutide: What to Know

Onyx Research Peptides Retatrutide is a research-only listing sold online. Here is what it is, what reviews and prices look like, and safety and legal facts.

↗
14
KNOWLEDGE ARTICLE

Pinnacle Peptides: What to Know Before You Buy

Pinnacle Peptides offers research-grade peptides such as BPC-157 and retatrutide. Read about reviews, discount codes, safety, and legal status before you buy.

↗